BEYONDSPRING INC (BYSI) Stock Price & Overview
NASDAQ:BYSI • KYG108301006
Current stock price
The current stock price of BYSI is 1.725 USD. Today BYSI is up by 0.88%. In the past month the price increased by 15.77%. In the past year, price increased by 28.73%.
BYSI Key Statistics
- Market Cap
- 72.312M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.25
- Dividend Yield
- N/A
BYSI Stock Performance
BYSI Stock Chart
BYSI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to BYSI. When comparing the yearly performance of all stocks, BYSI is one of the better performing stocks in the market, outperforming 72.11% of all stocks.
BYSI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BYSI. Both the profitability and financial health of BYSI have multiple concerns.
BYSI Earnings
BYSI Forecast & Estimates
BYSI Groups
Sector & Classification
BYSI Financial Highlights
Over the last trailing twelve months BYSI reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 49.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.89% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BYSI Ownership
BYSI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BYSI
Company Profile
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Company Info
IPO: 2017-03-09
BEYONDSPRING INC
100 Campus Drive, West Side, 4Th Floor, Suite 410
Florham Park NEW JERSEY 10005 US
CEO: Lan Huang
Employees: 40
Phone: 16465284184
BEYONDSPRING INC / BYSI FAQ
What does BYSI do?
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Can you provide the latest stock price for BEYONDSPRING INC?
The current stock price of BYSI is 1.725 USD. The price increased by 0.88% in the last trading session.
Does BEYONDSPRING INC pay dividends?
BYSI does not pay a dividend.
What is the ChartMill rating of BEYONDSPRING INC stock?
BYSI has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists BYSI stock?
BYSI stock is listed on the Nasdaq exchange.
What is the next earnings date for BYSI stock?
BEYONDSPRING INC (BYSI) will report earnings on 2026-05-13.
Can you provide the ownership details for BYSI stock?
You can find the ownership structure of BEYONDSPRING INC (BYSI) on the Ownership tab.